Disclosure certainty 4/5 debate potential 2/5

MSK sizes early-stage emerging managers at half a typical allocation

Jason Klein · Jarrid Tingle and Henri Pierre-Jacques – Harlem Capital (Manager Meetings, EP.24) · Dec 16, 2021 · at 10:23

Jason Klein, CIO of Memorial Sloan Kettering, describes how MSK manages risk when committing capital to first-time or emerging fund managers.

0:00 / 0:06exact quote · 6.7s
720p mp4 · rendered on demand · StarZero watermark
“We tend to size that at about half the size of where we would size an initial relationship, all things equal.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

More from Jason Klein

Insight
Klein: True institutional risk is loss sensitivity and liquidity, not volatility
“And by risk there, I don't really mean standard deviation or volatility, but I mean, what's the sensitivity to loss? What's the sensitivity to accessing their capital? How does their capital figure into their plans and their aspirations? And understanding How …”
Jason Klein Oct 9, 2017 ▶ 13:19 Jason Klein – Investing to Cure Cancer (Capital Allocators, EP.28)
Insight
Klein: Memorial Sloan Kettering targets a 100 bps annual illiquidity premium
“And then we came up with a Simple heuristic. Basically a hundred basis points per year. We think that we should be getting in terms of an illiquidity premium to lock up our money.”
Jason Klein Oct 9, 2017 ▶ 17:31 Jason Klein – Investing to Cure Cancer (Capital Allocators, EP.28)
Insight
Klein: Platforms Like Seeking Alpha Offer Allocators Genuine Investment Edge
“You look at the kind of information that people are sharing On Stock Guru, or Seeking Alpha, and you realize that a lot of the people that are sharing that information, or on Quora, for example, you realize that a lot of the people that are sharing information…”
Jason Klein Oct 9, 2017 ▶ 51:53 Jason Klein – Investing to Cure Cancer (Capital Allocators, EP.28)
Disclosure
Klein: MSK backed Harlem Capital for returns, not purely diversity
“And we didn't approach them as a diverse manager per se. We approached them as a manager that was going to make a lot of money and had a good objective, a good strategy, a good philosophy.”
Jason Klein Dec 16, 2021 ▶ 5:28 Jarrid Tingle and Henri Pierre-Jacques – Harlem Capital (Manager Meetings, EP.24)
Insight
Klein: Deep specialized niche research creates substantial institutional investment edge
“The investment world is is a is a series of smaller worlds that are quirky, that are funky, that are differently understood, that are driven by some set of underlying fundamentals in the longer term, but many sets of technicals in the near time. Taking the tim…”
Jason Klein Oct 9, 2017 ▶ 12:23 Jason Klein – Investing to Cure Cancer (Capital Allocators, EP.28)
Insight
Klein: Manager track records must link back to ex-ante research engines
“Ideally, you'd have a manager that has been doing The same strategy for a long period of time. So we should be able to see our way mapping a manager's research engine to the returns that they actually have produced. And then if you have that benefit of the tra…”
Jason Klein Oct 9, 2017 ▶ 20:30 Jason Klein – Investing to Cure Cancer (Capital Allocators, EP.28)
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 700 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.